These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 22130134

  • 1. 5-sulfonyl-benzimidazoles as selective CB2 agonists-part 2.
    Gijsen HJ, De Cleyn MA, Surkyn M, Van Lommen GR, Verbist BM, Nijsen MJ, Meert T, Wauwe JV, Aerssens J.
    Bioorg Med Chem Lett; 2012 Jan 01; 22(1):547-52. PubMed ID: 22130134
    [Abstract] [Full Text] [Related]

  • 2. 5-Sulfonyl-benzimidazoles as selective CB2 agonists.
    Verbist BM, De Cleyn MA, Surkyn M, Fraiponts E, Aerssens J, Nijsen MJ, Gijsen HJ.
    Bioorg Med Chem Lett; 2008 Apr 15; 18(8):2574-9. PubMed ID: 18394887
    [Abstract] [Full Text] [Related]

  • 3. The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives.
    Omura H, Kawai M, Shima A, Iwata Y, Ito F, Masuda T, Ohta A, Makita N, Omoto K, Sugimoto H, Kikuchi A, Iwata H, Ando K.
    Bioorg Med Chem Lett; 2008 Jun 01; 18(11):3310-4. PubMed ID: 18440813
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Novel benzimidazole derivatives as selective CB2 agonists.
    Pagé D, Balaux E, Boisvert L, Liu Z, Milburn C, Tremblay M, Wei Z, Woo S, Luo X, Cheng YX, Yang H, Srivastava S, Zhou F, Brown W, Tomaszewski M, Walpole C, Hodzic L, St-Onge S, Godbout C, Salois D, Payza K.
    Bioorg Med Chem Lett; 2008 Jul 01; 18(13):3695-700. PubMed ID: 18522867
    [Abstract] [Full Text] [Related]

  • 7. Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain.
    Brindisi M, Maramai S, Gemma S, Brogi S, Grillo A, Di Cesare Mannelli L, Gabellieri E, Lamponi S, Saponara S, Gorelli B, Tedesco D, Bonfiglio T, Landry C, Jung KM, Armirotti A, Luongo L, Ligresti A, Piscitelli F, Bertucci C, Dehouck MP, Campiani G, Maione S, Ghelardini C, Pittaluga A, Piomelli D, Di Marzo V, Butini S.
    J Med Chem; 2016 Mar 24; 59(6):2612-32. PubMed ID: 26888301
    [Abstract] [Full Text] [Related]

  • 8. Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands.
    Worm K, Zhou QJ, Saeui CT, Green RC, Cassel JA, Stabley GJ, DeHaven RN, Conway-James N, LaBuda CJ, Koblish M, Little PJ, Dolle RE.
    Bioorg Med Chem Lett; 2008 May 01; 18(9):2830-5. PubMed ID: 18430570
    [Abstract] [Full Text] [Related]

  • 9. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
    Cheng Y, Albrecht BK, Brown J, Buchanan JL, Buckner WH, DiMauro EF, Emkey R, Fremeau RT, Harmange JC, Hoffman BJ, Huang L, Huang M, Lee JH, Lin FF, Martin MW, Nguyen HQ, Patel VF, Tomlinson SA, White RD, Xia X, Hitchcock SA.
    J Med Chem; 2008 Aug 28; 51(16):5019-34. PubMed ID: 18680277
    [Abstract] [Full Text] [Related]

  • 10. Optimisation of a novel series of selective CNS penetrant CB(2) agonists.
    Watson C, Owen DR, Harding D, Kon-I K, Lewis ML, Mason HJ, Matsumizu M, Mukaiyama T, Rodriguez-Lens M, Shima A, Takeuchi M, Tran I, Young T.
    Bioorg Med Chem Lett; 2011 Jul 15; 21(14):4284-7. PubMed ID: 21669533
    [Abstract] [Full Text] [Related]

  • 11. Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.
    Manley PJ, Zartman A, Paone DV, Burgey CS, Henze DA, Della Penna K, Desai R, Leitl MD, Lemaire W, White RB, Yeh S, Urban MO, Kane SA, Hartman GD, Bilodeau MT, Trotter BW.
    Bioorg Med Chem Lett; 2011 Apr 15; 21(8):2359-64. PubMed ID: 21420857
    [Abstract] [Full Text] [Related]

  • 12. The pharmacology of cannabinoid receptors and their ligands: an overview.
    Pertwee RG.
    Int J Obes (Lond); 2006 Apr 15; 30 Suppl 1():S13-8. PubMed ID: 16570099
    [Abstract] [Full Text] [Related]

  • 13. Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies.
    Lange JH, van der Neut MA, Wals HC, Kuil GD, Borst AJ, Mulder A, den Hartog AP, Zilaout H, Goutier W, van Stuivenberg HH, van Vliet BJ.
    Bioorg Med Chem Lett; 2010 Feb 01; 20(3):1084-9. PubMed ID: 20031412
    [Abstract] [Full Text] [Related]

  • 14. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
    Whiteside GT, Gottshall SL, Boulet JM, Chaffer SM, Harrison JE, Pearson MS, Turchin PI, Mark L, Garrison AE, Valenzano KJ.
    Eur J Pharmacol; 2005 Dec 28; 528(1-3):65-72. PubMed ID: 16316650
    [Abstract] [Full Text] [Related]

  • 15. Design and optimization of benzimidazole-containing transient receptor potential melastatin 8 (TRPM8) antagonists.
    Parks DJ, Parsons WH, Colburn RW, Meegalla SK, Ballentine SK, Illig CR, Qin N, Liu Y, Hutchinson TL, Lubin ML, Stone DJ, Baker JF, Schneider CR, Ma J, Damiano BP, Flores CM, Player MR.
    J Med Chem; 2011 Jan 13; 54(1):233-47. PubMed ID: 21128593
    [Abstract] [Full Text] [Related]

  • 16. Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists.
    Raitio KH, Savinainen JR, Vepsäläinen J, Laitinen JT, Poso A, Järvinen T, Nevalainen T.
    J Med Chem; 2006 Mar 23; 49(6):2022-7. PubMed ID: 16539390
    [Abstract] [Full Text] [Related]

  • 17. Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.
    Chu GH, Saeui CT, Worm K, Weaver DG, Goodman AJ, Broadrup RL, Cassel JA, DeHaven RN, LaBuda CJ, Koblish M, Brogdon B, Smith S, Le Bourdonnec B, Dolle RE.
    Bioorg Med Chem Lett; 2009 Oct 15; 19(20):5931-5. PubMed ID: 19736007
    [Abstract] [Full Text] [Related]

  • 18. Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
    Brogi S, Corelli F, Di Marzo V, Ligresti A, Mugnaini C, Pasquini S, Tafi A.
    Eur J Med Chem; 2011 Feb 15; 46(2):547-55. PubMed ID: 21183257
    [Abstract] [Full Text] [Related]

  • 19. Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain.
    LaBuda CJ, Koblish M, Little PJ.
    Eur J Pharmacol; 2005 Dec 19; 527(1-3):172-4. PubMed ID: 16316653
    [Abstract] [Full Text] [Related]

  • 20. Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.
    Hollinshead SP, Tidwell MW, Palmer J, Guidetti R, Sanderson A, Johnson MP, Chambers MG, Oskins J, Stratford R, Astles PC.
    J Med Chem; 2013 Jul 25; 56(14):5722-33. PubMed ID: 23795771
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.